Expression of IGFBP-rP1 in ovarian and breast cancers in association with diabetes mellitus status
- Author:
Siti Norasikin Mohd Nafi
1
Author Information
1. Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia
- Collective Name:Siti Norasikin Mohd Nafi; Ab Hamid Siti Azrin; Anani Aila Mat Zin; Nor Hayati Othman; Nur Asyilla Che Jalil
- Publication Type:Journal Article
- Keywords:
Breast cancer;
ovarian cancer;
IGFBP-rP1, T2DM;
insulin;
IHC
- MeSH:
Breast cancer;
ovarian cancer
- From:The Malaysian Journal of Pathology
2019;41(1):33-39
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is an important component of the IGF system that regulates insulin resistance-related to tumour development. The aim of this study is to investigate the expression of IGFBP-rP1 among female cancer patients who are known or not known to have Type 2 Diabetes Mellitus (T2DM). Materials and Methods: Using a cross-sectional design, cases of ovarian and breast cancer with clinical status of T2DM were selected over a 10-year period in Hospital Universiti Sains Malaysia. Immunohistochemical staining for IGFBP-rP1 was performed on paraffin-embedded tissues and the results were correlated with the patient’s demographic and clinicopathological data. Results: A total of 152 breast cancer patients were recruited into the current study with 33.5% (51/152) patients were positive T2DM. Most of the breast cancer patients with T2DM were IGFBP-rP1-negative (66.7%, 34/51). The IGFBP-rP1 expression was significantly difference between breast cancer subjects with and without T2DM (p<0.001). There was no significant association of IGFBP-rP1 expression with data on the demographic and clinicopathological profiles of patients with breast cancer. Meanwhile, positive IGFBP-rP1 expression was evident in 44 out of 108 (40.74%) ovarian cancer cases. Among these cases, 36 were T2DM. In contrast to breast cancer cases, IGFBP-rP1 was mostly expressed among ovarian cancer patients with T2DM (66.7%, 24/36, p < 0.001). However, the -positive expression was not significantly associated with any sociodemographic and clinicopathological features of ovarian cancers. Conclusions: Majority of breast cancer patients with T2DM did not express IGFBP-rP1. In contrast, majority of the ovarian cancer patients with T2DM expressed IGFBP-rP1.
- Full text:5.2019my0989.pdf
